Search Results - therapeutics

482 Results

Sort By:

bio-IB3

Unmet NeedAccording to the CDC, approximately 5.8-million individuals aged 65+ in the United States were living with Alzheimer’s disease in 2020 (see CDC). Alzheimer’s disease leads to memory impairment that progressively affects the ability of individuals to conduct daily tasks and worsens with time. Currently, the diagnosis of Alzheimer’s disease...

Published: 3/12/2026 | Inventor(s): Esther Oh, Stina Tucker, David Borchelt, Juan Troncoso

Keywords(s): Alzheimer's Disease, Antibodies, Biologics, CNS and Neurological Disorders, Discovery/Research Tools, Disease Indication, Neurodegeneration, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Translational Research Biomarker

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Geriatrics, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Research Tools > Antibodies, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Neurology, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration

Non-intuitive combination of drug delivery carriers of the same drug for synergistic growth delay of solid tumors

Non-intuitive combination of drug delivery carriers of the same drug for synergistic growth delay of solid tumorsJHU Ref #: C15411 Unmet NeedCancer is the second leading cause of death in the United States, with an estimated 1.8 million cases having been diagnosed and 606,520 people having succumbed to the disease in 2020. The most common cancer diagnosis...

Published: 3/13/2026 | Inventor(s): Stavroula Sofou, Alaina Howe

Keywords(s): Breast Cancer, Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology

Compositions and Methods for Treatment of Eye Diseases

Unmet NeedOxidative stress contributes to the progression of multiple eye disorders, including retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy. Ocular oxidative stress is caused by an imbalance of antioxidants and pro-oxidants in the eye, leading to elevated levels of free radicals. Free radicals contribute to the damage...

Published: 3/13/2026 | Inventor(s): Peter Campochiaro, Andrea Cook

Keywords(s): Disease Indication, Eye Disorders, Non-novel, Predicted Novelty, Retinitis pigmentosa, Single, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Ophthalmology > Retinitis Pigmentosa, Clinical and Disease Specializations > Rare Diseases

Combinations of ASOs for the Modulation of SMN Expression in SMA Patients

Unmet NeedSpinal muscular atrophy (SMA) is a devastating neuromuscular disease that predominantly affects children and is the most common cause of hereditary infant mortality. The disease is caused by low levels of survival motor neuron (SMN) protein, due to recessive mutations in the SMN1 gene. Importantly, the copy number variation of SMN2, a homologous...

Published: 3/13/2026 | Inventor(s): Charlotte Sumner, Constantin d'Ydewalle, Frank Rigo, C. Bennett

Keywords(s): CNS and Neurological Disorders, Combination, Disease Indication, Drug Delivery Vehicle, Muscle Atrophy, Muscular Disorders, Neurodegenerative Diseases, Peptides/Prodrugs, Single, Targeted Therapy, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Neurology > Motor Neuron Diseases, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Proteins

L2 Lipopeptide Vaccine for Prevention of Human Papillomavirus Infection

C10218: L2 Lipopeptide Vaccine for Prevention of Human Papillomavirus Infection Value Proposition: • A broadly protective vaccine against HPV. • Can be delivered without needles. • Can be chemically synthesized at low cost. Technical Details: Human papillomavirus (HPV) infections are the most common sexually transmitted infection in the...

Published: 3/12/2026 | Inventor(s): Hannah Alphs-Jackson, Ratish Gambhira, Richard Roden

Keywords(s): Biologics, Cancers, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities

Co-assembling Peptide Hydrogels

The compositions and methods disclosed herein pertain to the manufacture and use of hydrogels. The disclosed compositions and methods pertain to hydrogels capable of induction by a variety of methodologies, such as by pH, salt and/or mixing. Such hydrogels are capable of self- or co-assembly and while doing so, may entrap a variety of bioactive agents...

Published: 3/12/2026 | Inventor(s): Yihua Yu, Sivakumar Ramachandran, Peter Flynn, Yiider Tseng

Keywords(s): Drug Delivery Vehicle, Hydrogel, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

New Therapeutic Approach for the Treatment of Neuropathic Pain

Unmet NeedChronic pain affects around 50-million adults within the United States (see CDC). Currently the dominant treatment option for moderate to severe pain are opioids, which have a range of associated adverse effects as well as the potential for abuse. Despite the development of abuse-deterrent formulations, opioid dependence remains a major challenge....

Published: 3/13/2026 | Inventor(s): Takashi Tsukamoto, Barbara Slusher, Niyada Hin, Camilo Rojas, Xinzhong Dong, Yun Guan, Ilyas Berhane

Keywords(s): Agonists/Promoters, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Small Molecules, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Pain > Chronic Neuropathic Pain, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Small Molecules

A peptide that forms pores in membranes at acidic pH for the delivery of macromolecules through the plasma membrane or endosomes, or the lysis of cancer cells.

Unmet Need There are significant roadblocks to the routine delivery of macromolecules such as proteins, peptides, imaging agents, polysaccharides and more to the cytosol of mammalian cells. While most macromolecules are easily directed to existing cellular uptake mechanisms, they are often trapped in endosomal pathways leading to lysosomal degradation...

Published: 3/12/2026 | Inventor(s): Kalina Hristova, Gregory Wiedman, William Wimley, Sarah Kim

Keywords(s): Biologics, Drug Delivery Vehicle, Peptide, Peptides/Prodrugs, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities

Targeting of Myeloid-Derived Suppressor Cells (MDSCs) for Cancer Treatment

Value Proposition· Addresses key resistance mechanism: targets MDSCs, a central driver of resistance to immune checkpoint inhibitors in metastatic and poorly immunogenic cancers· Synergistic combination strategy: Combines epigenetic modulators (HDAC and DNA methyltransferase inhibitors) with anti-PD-1 and anti-CTLA-4 antibodies to restore...

Published: 3/12/2026 | Inventor(s): KiBem Kim, Bert Vogelstein, Kenneth Kinzler, Shibin Zhou

Keywords(s): Antagonists/Inhibitors, Antibodies, Biologics, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Unpowered Respiratory Protective Hood

Value Proposition· Reduces contamination risk in doffing procedures: The integrated design of the disclosed technology simplifies the removal of PPE components, reducing doffing errors (self-contamination from mistakes when removing PPE). · Dual-pathway ventilation design: Bilayer check valves direct filtered air across the face shield (preventing...

Published: 3/12/2026 | Inventor(s): Matthew Petney, Patience Osei, Laura Scavo, Youseph Yazdi, William Patterson

Keywords(s): Orthotic Device, Orthotics, Therapeutic Devices, Therapeutics

Category(s): Technology Classifications > Medical Devices > Orthopedic Devices, Technology Classifications > Medical Devices > Therapeutic Devices, Technology Classifications > Medical Devices

1 2 3 4 5 6 7 8 9 10 ...